Unless there are specific contraindications, most patients with C3G should receive therapy with angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) as first-line therapy for proteinuria and hypertension. Both classes of agents have been effective in other glomerular diseases in slowing progression to renal failure. Additional measures include considering statin therapy to achieve target cholesterol and low-density lipoprotein cholesterol goals. Once supportive care is in place, the benefit of appropriate immunosuppressive therapy, if any, is evaluated. Generally, patients who receive any kind of immunosuppression achieve better outcomes than do patients who are treated conservatively with supportive care only.
There is currently no solid evidence regarding the efficacy of plasma therapy in the treatment of C3G.
Learn more about ACE inhibitors and ARBs for patients with C3G.
Medscape © 2023 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: A. Brent Alper. Fast Five Quiz: C3G Management - Medscape - Apr 24, 2023.